ROIV · Roivant Sciences Ltd.
Market Cap
$24.93B
Shares
722.32M
ROIV metrics
64 of 114 screener metrics currently available.
Market overview
2 metricsShare price
$34.41
Market cap
$24.93B
Price action
19 metricsPrice change (1W)
-7.0%
Price change (30D)
-1.2%
Price change (3M)
+19.1%
Price change (6M)
+15.8%
Price change (YTD)
+57.5%
Price change (1Y)
+175.9%
Trailing year
Price change (5Y)
+243.5%
52-week high
$37.58
52-week low
$12.39
Change from 52-week high
-9.0%
Change from 52-week low
+175.9%
Annualized volatility
43.1%
Beta
1.1
RSI (14D)
41.4
Price vs SMA 50
-3.0%
Price vs SMA 200
+20.6%
Avg volume (3M)
6.16M
Relative volume
1.0
Average dollar volume
$210.79M
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
722.32M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
3,310.5×
reciprocal yield 0.0%
P / book
5.9
reciprocal yield 17.0%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-0.9%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
50.3×
reciprocal yield 2.0%
EV / revenue historical average (5Y)
50.3×
reciprocal yield 2.0%
EV / EBIT historical average (3Y)
0.6×
reciprocal yield 172.4%
EV / EBIT historical average (5Y)
0.6×
reciprocal yield 172.4%
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
2026-08-06
Profitability
9 metricsGross margin
—
Operating margin
-7,914.8%
Trailing 12 months
Net margin
-2,837.7%
Gross profit (TTM)
—
Operating profit (TTM)
−$596.14M
Net income (TTM)
−$213.73M
Trailing 12 months
Diluted EPS (TTM)
$-0.47
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
-33.5%
Year over year
Net income growth YoY
—
Revenue (TTM)
$7.53M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+6.0%
Year over year · more shares
Revenue CAGR (3Y)
-36.0%
Revenue CAGR (5Y)
-19.1%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
-5.1%
Return on assets
-4.0%
Debt / equity
—
Current ratio
16.7
EBITDA (TTM)
−$593.29M
Free cash flow (TTM)
—
Quick ratio
—
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$1.25B
Total assets
$5.31B
Total debt
$323.72M
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$816.47M
Capital expenditures (TTM)
—
R&D (TTM)
$730.91M
SG&A (TTM)
$679.77M
Stock compensation (TTM)
$347.33M
R&D / revenue
9,704.0%
Stock compensation / revenue
4,611.4%
Ownership (13F)
3 metrics13F filers
498
13F filer change QoQ
+50
Institutional ownership
79.7%
Short interest
3 metricsShort interest
4.2%
Latest settlement · 5.0 days to cover
Days to cover
5.0d
Short-squeeze score
57 / 100
Insider activity
2 metricsNet insider buying (90D)
−$247.51M
Insider-sentiment score
6 / 100
Risk flags
1 metricsGoing concern
—
Key facts
CIK
1635088
CUSIP
G76279101
13F (30d)
345 filings
339 filers
Visit website
Investor relations